Skip to content
value.today

Biogen Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, -0.9% a year (statements).

%

US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $37.5 B means free cash flow growing 7.7% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.

Revenue grew -0.9% a year over the last three years.

Cash-flow value of the shares
$18.4 B
-51% against the market value
Value of the whole business
$21.7 B
before net debt
Value from after year 10
45%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-5.94%-3.44%-0.94%1.56%4.06%
7.92%-56%-45%-31%-14%+6%
8.92%-63%-54%-43%-29%-12%
9.92%-68%-60%-51%-39%-26%
10.92%-72%-65%-57%-48%-36%
11.92%-75%-69%-62%-54%-44%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Pharmaceutical: $23.7 B to $65.1 B, median $49.9 BPrice to salesPrice to sales of Pharmaceutical: $15.0 B to $66.3 B, median $34.2 BPrice to bookPrice to book of Pharmaceutical: $38.9 B to $149.3 B, median $74.7 BCash-flow value$0 M$40.3 B$80.6 B$121.0 B$161.3 BMarket value $37.5 B

Your own DCF model

A full discounted-cash-flow model of Biogen Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times Biogen Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Biogen Inc.Applied toValue (25th to 75th)Companies
P/E18.4× / 38.6× / 50.3×108.0×net income $1.3 B$23.7 B to $65.1 B53
Price to sales1.5× / 3.5× / 6.7×3.6×revenue $9.9 B$15.0 B to $66.3 B68
Price to book2.1× / 4.1× / 8.2×2.1×book equity $18.3 B$38.9 B to $149.3 B62

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Biogen Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

45.0×

Now above its median of 14.3×, in the top quarter of its range; range 6.4× to 45.0× over 30 months.

0×11×22×34×45×2020202120222023202420252026P/E 45×Median 14×

Price to sales

3.7×

Now above its median of 2.6×, in the top quarter of its range; range 1.8× to 5.5× over 30 months.

0×1×3×4×5×2020202120222023202420252026Price to sales 4×Median 3×

Price to book

2.1×

Now above its median of 1.6×, in the top quarter of its range; range 1.1× to 5.7× over 30 months.

0×1×3×4×6×2020202120222023202420252026Price to book 2×Median 2×

as of Oct 23, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 23, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$9.9 B$1.3 B$2.2 B$154 M$2.1 B$3.3 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$9.7 B$1.6 B$2.9 B$154 M$2.7 B$2.2 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$9.8 B$1.2 B$1.5 B$277 M$1.3 B$5.7 BSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$10.2 B$3.0 B$1.4 B$240 M$1.1 B$2.9 BSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$11.0 B$1.6 B$3.6 B$258 M$3.4 B$4.0 BSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$13.4 B$4.0 B$4.2 B$425 M$3.8 B$6.1 BSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $37.5 B on Oct 23, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.